| Q36512766 | 1α,25-Dihydroxyvitamin D3-liganded vitamin D receptor increases expression and transport activity of P-glycoprotein in isolated rat brain capillaries and human and rat brain microvessel endothelial cells |
| Q39437881 | Amyloid beta: structure, biology and structure-based therapeutic development |
| Q53415989 | Amyloid efflux transporter expression at the blood-brain barrier declines in normal aging. |
| Q35166482 | Amyloid-β efflux from the central nervous system into the plasma |
| Q28740991 | Association of plasma Aß peptides with blood pressure in the elderly |
| Q43962625 | Beta-amyloid deposition in the brains of rats chronically infused with thiorphan or lipopolysaccharide: the role of ascorbic acid in the vehicle |
| Q27318080 | Blood platelets in the progression of Alzheimer's disease |
| Q50778486 | Blood-brain barrier P-glycoprotein function in Alzheimer's disease. |
| Q36492343 | Cholesterol and 24S-hydroxycholesterol trafficking in Alzheimer's disease |
| Q48408756 | Circulating amyloid-beta peptide crosses the blood-brain barrier in aged monkeys and contributes to Alzheimer's disease lesions |
| Q26801541 | Clearance systems in the brain-implications for Alzheimer disease |
| Q38905832 | Common Pesticide, Dichlorodiphenyltrichloroethane (DDT), Increases Amyloid-β Levels by Impairing the Function of ABCA1 and IDE: Implication for Alzheimer's Disease |
| Q37737296 | Current therapeutic targets for the treatment of Alzheimer's disease |
| Q38542827 | Dissecting the Contribution of Vascular Alterations and Aging to Alzheimer's Disease |
| Q42225006 | Efflux of human and mouse amyloid β proteins 1–40 and 1–42 from brain: impairment in a mouse model of alzheimer's disease |
| Q36071927 | High-Throughput Screening for Identification of Blood-Brain Barrier Integrity Enhancers: A Drug Repurposing Opportunity to Rectify Vascular Amyloid Toxicity. |
| Q53250185 | Human antibodies against amyloid beta peptide: a potential treatment for Alzheimer's disease. |
| Q47102588 | Intermittent Fasting Protects against Alzheimer's Disease Possible through Restoring Aquaporin-4 Polarity |
| Q22001054 | Intracellular Aβ pathology and early cognitive impairments in a transgenic rat overexpressing human amyloid precursor protein: a multidimensional study. |
| Q37880893 | Intranasal delivery of therapeutic proteins for neurological diseases. |
| Q38008724 | Is RAGE still a therapeutic target for Alzheimer's disease? |
| Q43074615 | Kaolin-induced chronic hydrocephalus accelerates amyloid deposition and vascular disease in transgenic rats expressing high levels of human APP. |
| Q34274025 | Low‐density lipoprotein receptor‐related protein‐1: a serial clearance homeostatic mechanism controlling Alzheimer’s amyloid β‐peptide elimination from the brain |
| Q48116760 | MDR1-P-Glycoprotein (ABCB1) Mediates Transport of Alzheimer's amyloid-beta peptides--implications for the mechanisms of Abeta clearance at the blood-brain barrier |
| Q44115983 | Modeling effect of a γ-secretase inhibitor on amyloid-β dynamics reveals significant role of an amyloid clearance mechanism |
| Q37858417 | Monocytes and Alzheimer's disease |
| Q35009772 | Neuroinflammation and anti-inflammatory therapy for Alzheimer's disease |
| Q47345987 | Neuroprotective effect of formononetin in ameliorating learning and memory impairment in mouse model of Alzheimer's disease |
| Q36075479 | Neurovascular pathways and Alzheimer amyloid beta-peptide |
| Q36876341 | New therapeutic targets in the neurovascular pathway in Alzheimer's disease |
| Q48406155 | Passage of amyloid beta protein antibody across the blood-brain barrier in a mouse model of Alzheimer's disease |
| Q44479225 | RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain |
| Q46132661 | Reduced estimated glomerular filtration rate in Alzheimer's disease |
| Q35894473 | Reference tissue normalization in longitudinal (18)F-florbetapir positron emission tomography of late mild cognitive impairment |
| Q24309440 | SRF and myocardin regulate LRP-mediated amyloid-beta clearance in brain vascular cells |
| Q39618144 | Selective antihypertensive dihydropyridines lower Aβ accumulation by targeting both the production and the clearance of Aβ across the blood-brain barrier |
| Q44938458 | Sevoflurane alters the expression of receptors and enzymes involved in Aβ clearance in rats |
| Q30871112 | Studying the neurovascular unit: an improved blood-brain barrier model |
| Q38097859 | Targeting ApoE4/ApoE receptor LRP1 in Alzheimer's disease |
| Q47188911 | Targeting Neuroinflammation to Treat Alzheimer's Disease. |
| Q38005630 | The role of inflammatory processes in Alzheimer's disease. |
| Q35009752 | Vascular disorder in Alzheimer's disease: role in pathogenesis of dementia and therapeutic targets |
| Q33705067 | Voluntary Exercise Promotes Glymphatic Clearance of Amyloid Beta and Reduces the Activation of Astrocytes and Microglia in Aged Mice |